ITERUM THERAPEUTICS PLC (ITRM)

Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN,...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!

ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023

ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.

ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Iterum Therapeutics (NASDAQ:ITRM) just reported results for the fourth quarter ...

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

--Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host...

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company...

Iterum meets main goal in late trial for uUTI treatment with oral sulopenem (NASDAQ:ITRM)

Iterum Therapeutics announced positive results from a phase 3 trial comparing oral sulopenem to Augmentin in women with urinary tract infections.

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

/PRNewswire/ -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics...

Iterum Therapeutics regains compliance with Nasdaq's minimum bid price rule (NASDAQ:ITRM)

Pharmaceutical company Iterum Therapeutics regains compliance with Nasdaq's minimum bid price rule, meeting the requirement after a non-compliance notice.

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

DUBLIN, Ireland and CHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical...

Iterum Therapeutics director discloses purchase of 20K shares (NASDAQ:ITRM)

Iterum Therapeutics director Michael W Dunne acquires 20k shares for $40,690, joining a series of insider trades on ITRM in the past year.

Iterum Therapeutics Reports Third Quarter 2023 Financial Results

-- Top-line Data for Pivotal REASSURE Trial Expected in Early Q1 2024 – --Resubmission of NDA for uUTI Expected in Q2 2024-- DUBLIN, Ireland and CHICAGO,...

Iterum Therapeutics to Present Data at IDWeek 2023

DUBLIN, Ireland and CHICAGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...

Iterum Therapeutics Reports Second Quarter 2023 Financial Results

--Expect to Complete Enrollment in Q1 2024; Topline Data Expected in Q2 2024 ----Cash Runway into Q3 2024-- DUBLIN, Ireland and CHICAGO, Aug. 11, 2023 ...

Iterum Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 11, 2023

DUBLIN, Ireland and CHICAGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...

Iterum Therapeutics to Present Data at ASM Microbe 2023

DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...

Iterum Therapeutics Reports First Quarter 2023 Financial Results

--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) --...

Iterum Therapeutics Presents Scientific Posters at ECCMID 2023 Highlighting Application of Desirability of Outcomes Ranking (DOOR) to two Registration Trials

DUBLIN, Ireland and CHICAGO, April 20, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...

Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

--Registration Trial for uUTI Ongoing and On Track----Cash Runway until Mid-2024-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland...

Iterum Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023

DUBLIN, Ireland and CHICAGO, March 09, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with an overview of the biggest pre-market stock movers traders need to know about for Monday!

Iterum Therapeutics Reports Employment Inducement Grant

Iterum Therapeutics Reports Employment Inducement Grant

DUBLIN, Ireland and CHICAGO, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum Therapeutics”), a clinical-stage...